Anionic pregnane compounds, method for their producing and use of them

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61388963%3A_____%2F14%3A00435943" target="_blank" >RIV/61388963:_____/14:00435943 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/67985823:_____/14:00435943

Výsledek na webu

<a href="http://worldwide.espacenet.com/publicationDetails/biblio?CC=EP&NR=2313424B1&KC=B1&FT=D&ND=5&date=20140423&DB=EPODOC&locale=en_EP" target="_blank" >http://worldwide.espacenet.com/publicationDetails/biblio?CC=EP&NR=2313424B1&KC=B1&FT=D&ND=5&date=20140423&DB=EPODOC&locale=en_EP</a>

DOI - Digital Object Identifier

—

Jazyk výsledku

angličtina

Název v původním jazyce

Anionic pregnane compounds, method for their producing and use of them

Popis výsledku v původním jazyce

This invention relates to pregnane anionic compounds of general formula I in which R1 is ester group, which is able to form ion such as sulfate, pyridinium sulfate, hemisuccinate etc., R2 is hydrogen atom in alpha or beta configuration, and R3 is ester group, as is acetoxy group, nicotinoyloxy group etc., and their pharmaceutically acceptable salts. Compounds of general formula I are preferably produced from the diol of formula II or diol of formula VIII, which are converted according to described sequence of reactions, to compounds of general formula I, in which R1 is ester group, which is able to form ion such as sulfate, pyridinium sulfate, hemisuccinate etc., R2 is hydrogen atom in alpha or beta configuration, and R3 is ester group. The compounds of general formula I are useful as active ingredients for production of pharmaceuticals for the treatment of neurological and psychiatric diseases and conditions associated with excessive activation of NMDA receptors such as neuroprotectiv

Název v anglickém jazyce

Anionic pregnane compounds, method for their producing and use of them

Popis výsledku anglicky

This invention relates to pregnane anionic compounds of general formula I in which R1 is ester group, which is able to form ion such as sulfate, pyridinium sulfate, hemisuccinate etc., R2 is hydrogen atom in alpha or beta configuration, and R3 is ester group, as is acetoxy group, nicotinoyloxy group etc., and their pharmaceutically acceptable salts. Compounds of general formula I are preferably produced from the diol of formula II or diol of formula VIII, which are converted according to described sequence of reactions, to compounds of general formula I, in which R1 is ester group, which is able to form ion such as sulfate, pyridinium sulfate, hemisuccinate etc., R2 is hydrogen atom in alpha or beta configuration, and R3 is ester group. The compounds of general formula I are useful as active ingredients for production of pharmaceuticals for the treatment of neurological and psychiatric diseases and conditions associated with excessive activation of NMDA receptors such as neuroprotectiv

Druh

P - Patent

CEP obor

CC - Organická chemie

OECD FORD obor

—

Projekt

<a href="/cs/project/GAP303%2F12%2F1464" target="_blank" >GAP303/12/1464: Studium modulačního vlivu neurosteroidů na NMDA receptory</a><br>

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2014

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Číslo patentu nebo vzoru

EP2313424

Vydavatel

EPO_1 -

Název vydavatele

European Patent Office

Místo vydání

Munich, The Hague, Berlin, Vienna, Brussels

Stát vydání

—

Datum přijetí

23. 4. 2014

Název vlastníka

Ústav organické chemie a biochemie AV ČR, v. v. i. - Fyziologický ústav AV ČR, v. v. i

Způsob využití

A - Výsledek využívá pouze poskytovatel

Druh možnosti využití

A - K využití výsledku jiným subjektem je vždy nutné nabytí licence